Cargando…

Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial

The current curative approaches for ischemia/reperfusion injury on liver transplantation are still under debate for their safety and efficacy in patients with end-stage liver disease. We present the SIMVA statin donor treatment before Liver Transplants study. METHODS. SIMVA statin donor treatment be...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagano, Duilio, Bosch, Jaime, Tuzzolino, Fabio, Oliva, Elisabetta, Ekser, Burcin, Zito, Giovanni, Cintorino, Davide, di Francesco, Fabrizio, Li Petri, Sergio, Ricotta, Calogero, Bonsignore, Pasquale, Calamia, Sergio, Magro, Bianca, Trifirò, Gianluca, Alduino, Rossella, Barbara, Marco, Conaldi, Pier Giulio, Gallo, Alessia, Venuti, Francesca, Luca, Angelo, Gruttadauria, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698118/
https://www.ncbi.nlm.nih.gov/pubmed/35862782
http://dx.doi.org/10.1097/TP.0000000000004220
_version_ 1784838736471654400
author Pagano, Duilio
Bosch, Jaime
Tuzzolino, Fabio
Oliva, Elisabetta
Ekser, Burcin
Zito, Giovanni
Cintorino, Davide
di Francesco, Fabrizio
Li Petri, Sergio
Ricotta, Calogero
Bonsignore, Pasquale
Calamia, Sergio
Magro, Bianca
Trifirò, Gianluca
Alduino, Rossella
Barbara, Marco
Conaldi, Pier Giulio
Gallo, Alessia
Venuti, Francesca
Luca, Angelo
Gruttadauria, Salvatore
author_facet Pagano, Duilio
Bosch, Jaime
Tuzzolino, Fabio
Oliva, Elisabetta
Ekser, Burcin
Zito, Giovanni
Cintorino, Davide
di Francesco, Fabrizio
Li Petri, Sergio
Ricotta, Calogero
Bonsignore, Pasquale
Calamia, Sergio
Magro, Bianca
Trifirò, Gianluca
Alduino, Rossella
Barbara, Marco
Conaldi, Pier Giulio
Gallo, Alessia
Venuti, Francesca
Luca, Angelo
Gruttadauria, Salvatore
author_sort Pagano, Duilio
collection PubMed
description The current curative approaches for ischemia/reperfusion injury on liver transplantation are still under debate for their safety and efficacy in patients with end-stage liver disease. We present the SIMVA statin donor treatment before Liver Transplants study. METHODS. SIMVA statin donor treatment before Liver Transplants is a monocentric, double-blind, randomized, prospective tial aiming to compare the safety and efficacy of preoperative brain-dead donors’ treatment with the intragastric administration of 80 mg of simvastatin on liver transplant recipient outcomes in a real-life setting. Primary aim was incidence of patient and graft survival at 90 and 180 d posttransplant; secondary end-points were severe complications. RESULTS. The trial enrolled 58 adult patients (18–65 y old). The minimum follow-up was 6 mo. No patient or graft was lost at 90 or 180 d in the experimental group (n = 28), whereas patient/graft survival were 93.1% (P = 0.016) and 89.66% (P = 0.080) at 90 d and 86.21% (P = 0.041) and 86.2% (P = 0.041) at 180 d in the control group (n = 29). The percentage of patients with severe complications (Clavien-Dindo ≥IIIb) was higher in the control group, 55.2% versus 25.0% in the experimental group (P = 0.0307). The only significant difference in liver tests was a significantly higher gamma-glutamyl transferase and alkaline phosphatase at 15 d (P = 0.017), (P = 0.015) in the simvastatin group. CONCLUSIONS. Donor simvastatin treatment is safe, and may significantly improve early graft and patient survival after liver transplantation, although further research is mandatory.
format Online
Article
Text
id pubmed-9698118
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-96981182022-11-28 Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial Pagano, Duilio Bosch, Jaime Tuzzolino, Fabio Oliva, Elisabetta Ekser, Burcin Zito, Giovanni Cintorino, Davide di Francesco, Fabrizio Li Petri, Sergio Ricotta, Calogero Bonsignore, Pasquale Calamia, Sergio Magro, Bianca Trifirò, Gianluca Alduino, Rossella Barbara, Marco Conaldi, Pier Giulio Gallo, Alessia Venuti, Francesca Luca, Angelo Gruttadauria, Salvatore Transplantation Original Clinical Science—Liver The current curative approaches for ischemia/reperfusion injury on liver transplantation are still under debate for their safety and efficacy in patients with end-stage liver disease. We present the SIMVA statin donor treatment before Liver Transplants study. METHODS. SIMVA statin donor treatment before Liver Transplants is a monocentric, double-blind, randomized, prospective tial aiming to compare the safety and efficacy of preoperative brain-dead donors’ treatment with the intragastric administration of 80 mg of simvastatin on liver transplant recipient outcomes in a real-life setting. Primary aim was incidence of patient and graft survival at 90 and 180 d posttransplant; secondary end-points were severe complications. RESULTS. The trial enrolled 58 adult patients (18–65 y old). The minimum follow-up was 6 mo. No patient or graft was lost at 90 or 180 d in the experimental group (n = 28), whereas patient/graft survival were 93.1% (P = 0.016) and 89.66% (P = 0.080) at 90 d and 86.21% (P = 0.041) and 86.2% (P = 0.041) at 180 d in the control group (n = 29). The percentage of patients with severe complications (Clavien-Dindo ≥IIIb) was higher in the control group, 55.2% versus 25.0% in the experimental group (P = 0.0307). The only significant difference in liver tests was a significantly higher gamma-glutamyl transferase and alkaline phosphatase at 15 d (P = 0.017), (P = 0.015) in the simvastatin group. CONCLUSIONS. Donor simvastatin treatment is safe, and may significantly improve early graft and patient survival after liver transplantation, although further research is mandatory. Lippincott Williams & Wilkins 2022-07-11 2022-12 /pmc/articles/PMC9698118/ /pubmed/35862782 http://dx.doi.org/10.1097/TP.0000000000004220 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Clinical Science—Liver
Pagano, Duilio
Bosch, Jaime
Tuzzolino, Fabio
Oliva, Elisabetta
Ekser, Burcin
Zito, Giovanni
Cintorino, Davide
di Francesco, Fabrizio
Li Petri, Sergio
Ricotta, Calogero
Bonsignore, Pasquale
Calamia, Sergio
Magro, Bianca
Trifirò, Gianluca
Alduino, Rossella
Barbara, Marco
Conaldi, Pier Giulio
Gallo, Alessia
Venuti, Francesca
Luca, Angelo
Gruttadauria, Salvatore
Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial
title Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial
title_full Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial
title_fullStr Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial
title_full_unstemmed Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial
title_short Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial
title_sort donor simvastatin treatment is safe and might improve outcomes after liver transplantation: a randomized clinical trial
topic Original Clinical Science—Liver
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698118/
https://www.ncbi.nlm.nih.gov/pubmed/35862782
http://dx.doi.org/10.1097/TP.0000000000004220
work_keys_str_mv AT paganoduilio donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT boschjaime donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT tuzzolinofabio donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT olivaelisabetta donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT ekserburcin donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT zitogiovanni donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT cintorinodavide donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT difrancescofabrizio donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT lipetrisergio donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT ricottacalogero donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT bonsignorepasquale donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT calamiasergio donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT magrobianca donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT trifirogianluca donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT alduinorossella donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT barbaramarco donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT conaldipiergiulio donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT galloalessia donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT venutifrancesca donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT lucaangelo donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial
AT gruttadauriasalvatore donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial